5 More Countries Approve Pfizer Arthritis Drug Xeljanz
Pfizer Inc.'s rheumatoid arthritis drug Xeljanz has received approval for use in five more countries, including Switzerland, the company said Monday, adding that it hoped a European Union health board would...To view the full article, register now.
Already a subscriber? Click here to view full article